Markus Schlaich
Overview
Explore the profile of Markus Schlaich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
4737
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mahfoud F, Townsend R, Kandzari D, Mancia G, Whitbourn R, Lauder L, et al.
JACC Adv
. 2025 Feb;
4(3):101606.
PMID: 39985884
Background: Renal denervation (RDN) lowers blood pressure (BP) in patients with uncontrolled hypertension. Current guidelines recommend RDN for patients with uncontrolled BP despite the use of antihypertensive (AH) medications. Durability...
2.
3.
Beaney T, Kerr G, Kiru G, McArdle H, Schlaich M, Schutte A, et al.
BMJ Glob Health
. 2024 Dec;
9(12).
PMID: 39622541
Introduction: Elevated blood pressure (BP) is the major contributor to mortality and disease burden worldwide. May Measurement Month (MMM) is a global BP screening campaign, which aims to raise awareness...
4.
Atkins E, Nguyen L, Chatterton M, Schlaich M, Schutte A, Rodgers A
Med J Aust
. 2024 Nov;
221(11):612-616.
PMID: 39580704
Objective: To quantify the costs of hypertension diagnosis and treatment in Australia, particularly in primary care, including general practices and pharmacies. Study Design: Economic analysis; analysis of Pharmaceutical Benefits Scheme...
5.
Castillo Rodriguez B, Secemsky E, Swaminathan R, Feldman D, Schlaich M, Battaglia Y, et al.
Am J Med
. 2024 Oct;
137(11):e221-e222.
PMID: 39461803
No abstract available.
6.
See A, Blazeska E, Shaban A, Thomas M, Nejad S, Dornelles A, et al.
Kidney Blood Press Res
. 2024 Sep;
49(1):843-851.
PMID: 39342925
Introduction: Sodium-glucose co-transporter 2 inhibitors (SGLT2is) have been shown to provide effective cardiorenal protection, reducing mortality in conditions such as heart failure and chronic kidney disease. While several mechanisms have...
7.
Larkins N, Choong C, Schlaich M, Quinlan C, Mynard J, Kim S, et al.
J Hypertens
. 2024 Sep;
42(11):1932-1939.
PMID: 39248111
Objectives: Current American Academy of Pediatrics (AAP) and European Society of Hypertension (ESH) thresholds defining hypertension in children use blood pressure (BP) normalised to age, sex and height. However, scare...
8.
Penaherrera E, Ramirez M, Penaherrera R, Duarte Y, Caceres S, Avila E, et al.
Eur Heart J Suppl
. 2024 Jul;
26(Suppl 3):iii31-iii34.
PMID: 39055599
Arterial hypertension is a growing burden worldwide, leading to over 10.8 million deaths each year. Before the outbreak of the COVID-19 pandemic, cardiovascular diseases were the main cause of death...
9.
Schutte A, Bennett B, Chow C, Cloud G, Doyle K, Girdis Z, et al.
Med J Aust
. 2024 Jul;
221(3):126-134.
PMID: 38990122
No abstract available.
10.
Gnanenthiran S, Barnhart M, Tan I, Zeng M, OHagan E, Gianacas C, et al.
Contemp Clin Trials
. 2024 Jun;
143:107610.
PMID: 38878995
High blood pressure (BP) is the leading preventable risk factor for death, but only one in three patients achieve target BP control. A key contributor to this problem is poor...